---
title: "Onco-Innovations identifies non-tin catalyst to advance ONC010 polymer development"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295714977.md"
description: "Onco-Innovations announced that Nanosoft Polymers identified a non-tin catalyst for ONC010 polymer synthesis to improve impurity control. A 300-gram development-scale API batch achieved 99.3% purity with undetectable residual solvents. The analytical reference standard program is complete, and polymer analytics using RI-GPC have advanced. Bioanalytical and pharmacokinetic studies are progressing to support IND-enabling work and a potential first-in-human study in Australia."
datetime: "2026-08-12T22:00:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295714977.md)
  - [en](https://longbridge.com/en/news/295714977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295714977.md)
generator: "portal-rs"
---

# Onco-Innovations identifies non-tin catalyst to advance ONC010 polymer development

-   Onco-Innovations reported Nanosoft Polymers identified a non-tin catalyst for ONC010 polymer synthesis, targeting tighter impurity control ahead of GMP. \* 300-gram development-scale API batch for ONC010 completed, showing about 99.3% purity with residual solvents below detection limits. \* Analytical reference standard program finished to support future identity, stability, impurity profiling, and batch comparability for the API. \* Polymer analytics advanced with RI-GPC to better control molecular-weight distribution and polydispersity, supporting nanoparticle formulation reproducibility. \* Bioanalytical, pharmacokinetic, and three-species metabolism studies progressed to support IND-enabling work and a potential first-in-human study in Australia. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202608121800TNWSWRCACNPR\_\_\_\_\_1AJ6FQl40) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ONCO.US](https://longbridge.com/en/quote/ONCO.US.md)

## Related News & Research

- [Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program](https://longbridge.com/en/news/296513179.md)
- [Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) Builds Foundation for Biomarker-Driven Cancer Therapy](https://longbridge.com/en/news/296130343.md)
- [Quest Diagnostics teams with Humanity to offer biological age analysis on Questhealth.com](https://longbridge.com/en/news/296926398.md)
- [Lexaria says DehydraTECH 3.0 retatrutide tablet boosts absorption up to 4,552% in dog study](https://longbridge.com/en/news/296793626.md)
- [09:57 ETHumanity führt über questhealth.com die Analyse des biologischen Alters in den USA ein](https://longbridge.com/en/news/296926366.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**